Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
Colorectal Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal Cancer,UFT,LV,Krestin,adjuvant therapy,phase III
Eligibility Criteria
Inclusion Criteria: Patients with primary colonic carcinoma or rectal carcinoma of histological stage III, who have undergone histological curability A or B surgeries Patients evaluated histologically as lymph node metastasis positive Patients aged between 20 and 80 years, inclusive, at the time of acquisition of informed consent Patients with performance status 0 to 2 Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy or immunotherapy) Gastrointestinal function: Patients with no diarrhea (watery stool) Patients without severe impairment of renal, hepatic and bone marrow functions Patients with no serious concurrent complications (such as infection) Patients who have given written informed consent to participate in this study Exclusion Criteria: Patients graded as curability C Patients with stenosis not capable of oral intake Among disease stage IIIa cases, those that are si/n(-) and ai/n(-) Patients with fresh hemorrhage from the gastrointestinal tract Patients with retention of body fluid necessitating treatment Patients with infection, intestinal palsy or intestinal occlusion Patients with the lower end of the tumor involving the peritoneal reflection Patients with lower rectal cancer (Rb), involving the anal canal (P) or perianal skin (E) Patients with active multiple cancers; or even if the multiple cancers are metachronous, have a disease-free period of less than 5 years (but excluding cancer in situ and skin cancer) Patients who are pregnant or hope to become pregnant during the study period Patients with poorly controlled diabetes or are treated by continuous use of insulin Patients with a history of ischemic heart disease Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have difficulties participating in the study Patients receiving continuous administration of steroids Patients who have experienced serious drug allergy in the past Others, patients judged by the investigator or subinvestigator to be inappropriate as subject
Sites / Locations
- ・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine)
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
2
3
1